Biomarkers of Duchenne muscular dystrophy: current findings
Open Access
- 1 January 2018
- journal article
- review article
- Published by Informa UK Limited in Degenerative Neurological and Neuromuscular Disease
- Vol. ume 8, 1-13
- https://doi.org/10.2147/dnnd.s121099
Abstract
Numerous biomarkers have been unveiled in the rapidly evolving biomarker discovery field, with an aim to improve the clinical management of disorders. In rare diseases, such as Duchenne muscular dystrophy, this endeavor has created a wealth of knowledge that, if effectively exploited, will benefit affected individuals, with respect to health care, therapy, improved quality of life and increased life expectancy. The most promising findings and molecular biomarkers are inspected in this review, with an aim to provide an overview of currently known biomarkers and the technological developments used. Biomarkers as cells, genetic variations, miRNAs, proteins, lipids and/or metabolites indicative of disease severity, progression and treatment response have the potential to improve development and approval of therapies, clinical management of DMD and patients’ life quality. We highlight the complexity of translating research results to clinical use, emphasizing the need for biomarkers, fit for purpose and describe the challenges associated with qualifying biomarkers for clinical applications.Keywords
This publication has 135 references indexed in Scilit:
- Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skippingHuman Molecular Genetics, 2012
- miRNAs as serum biomarkers for Duchenne muscular dystrophyEMBO Molecular Medicine, 2011
- Chronic Systemic Therapy With Low-dose Morpholino Oligomers Ameliorates the Pathology and Normalizes Locomotor Behavior in mdx MiceMolecular Therapy, 2011
- Combination of Myostatin Pathway Interference and Dystrophin Rescue Enhances Tetanic and Specific Force in Dystrophic mdx MiceMolecular Therapy, 2010
- Octa-guanidine Morpholino Restores Dystrophin Expression in Cardiac and Skeletal Muscles and Ameliorates Pathology in Dystrophic mdx MiceMolecular Therapy, 2009
- Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophyHuman Molecular Genetics, 2009
- Proteomic profiling of antisense‐induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic mdx diaphragmProteomics, 2009
- MicroRNA-206: The skeletal muscle-specific myomiRBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2008
- Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomerProceedings of the National Academy of Sciences of the United States of America, 2008
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008